Form 4 for CRSP CRISPR Therapeutics AG
Accepted 2021-12-03 00:00:00 ET · period of report 2021-12-02 · accession 0001209191-21-068014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-03 | 2021-12-02 | CRSP | KASINGER JAMES R. | GC, Sec | M - OptEx | $13.62 | +7,342 | 36.5K | +25% | +$100.0K |
| D | 2021-12-03 | 2021-12-02 | CRSP | KASINGER JAMES R. | GC, Sec | M - OptEx | $0.00 | -7,342 | 93.6K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2021-12-02 | M | A | 7,342 | $13.62 | 36,512 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-12-02 | M | D | 7,342 | $0.00 | 93,632 | D | $13.62 · — to 2027-05-31 | 7,342 Common Shares | (F1) This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% vested on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months. |